Fluctuations in the plasma angiotensin I converting enzyme activity during long-term treatment with captopril

Acta Cardiol. 1982;37(1):1-9.

Abstract

Eight hypertensive patients on chronic captopril treatment were studied: blood pressure, plasma converting enzyme activity (pCEA) and various components of plasma renin-angiotensin-aldosterone system were measured repeatedly, immediately before and up to 7 hours after the usual morning dose of captopril in 5 patients, or a matching placebo in 3 patients. In the patients, receiving a placebo no significant changes were observed over a 7 hour period in pCEA, plasma rénin activity (PRA), plasma angiotensin II (ANG II) plasma aldosterone (PAC) and blood pressure. In patients receive captopril (200 mg) pCEA rapidly decreased, reaching after 2 hours a minimum, corresponding to nearly 20 per cent of its reference value. Thereafter pCEA increased and after 7 hours remained only slightly depressed. Within the first hour after captopril intake a small but significant decrease of ANG II and PAC was observed, while PRA and blood pressure remained unchanged throughout the study period. A continuous low pCEA level is therefore not necessary to achieve a sustained blood pressure lowering effect during chronic captopril treatment.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aldosterone / blood
  • Angiotensin II / blood
  • Blood Pressure / drug effects*
  • Captopril / therapeutic use*
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / enzymology
  • Male
  • Middle Aged
  • Peptidyl-Dipeptidase A / blood*
  • Proline / analogs & derivatives*
  • Renin / blood

Substances

  • Angiotensin II
  • Aldosterone
  • Proline
  • Captopril
  • Peptidyl-Dipeptidase A
  • Renin